FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2265915051> ?p ?o ?g. }

• W2265915051 endingPage "e19656" @default.
• W2265915051 startingPage "e19656" @default.
• W2265915051 abstract "e19656 Background: Despite improvements in the outcome of solid malignancy, a great number of patients (pts) will died from their affliction. The timing for cessation of oncologic treatment is difficult to establish. Furthermore, It would be useful, to have economic data of the end of life (EOL). This approach is rarely achieved in a French system of care. Methods: In order to collect data about therapy in the EOL and to understand the decision process, we performed a study in a French anticancer center. Results: From November 2008 to May 2009, we observed all adult pts treated in one single institution by at least one chemotherapy regimen for solid malignancy died from the evolution of disease, therapy-related complications or secondary neoplasm. 62 pts died in this period. Median age at death was 69. Colorectal (7), breast (8), lung (8) and head and neck (8) cancer were 50 % of the pts. Median time between diagnosis and death was 25.2 months. Median time between diagnosis of metastases and death was 11.4 months. Pts have received a median line of treatment of 2.5, 14 pts received 4 line or more. 54 pts died of terminal disease, although 8 pts died of acute complications. Among the 62 pts, 29% received chemotherapy or immunotherapy the last 4 wks and 48% the last 8 wks, corresponding to 726,22 € and 1566,37 € per treated pts. Among pts received therapy the last 8 wks, median time between last regimen and death was 13 days. As we found no toxic deaths, 2 pts died just after chemotherapy (3 and 1 days). We can estimate that 29% of the 62 pts had received a probably useless or nonevaluated therapy for efficacy, the last 4 wks. No predictive clinical factors have been found to understand the decision process. No correlation has been found between demographic characteristics of medical doctor and the decision process. 95% of pts have been informed of prognosis, in the last 4 wks. In 90% of pts, relatives and/or pts have been associated to decision of treatment. Conclusions: These preliminary data suggest, in EOL, the requirement to use evaluated clinical scale to indicate oncologic treatment, the need to evaluate toxic deaths, and to assess pertinence and efficacy of chemotherapy or biotherapy, including an economic approach. No significant financial relationships to disclose." @default.
• W2265915051 created "2016-06-24" @default.
• W2265915051 creator A5019873099 @default.
• W2265915051 creator A5022732830 @default.
• W2265915051 creator A5037206907 @default.
• W2265915051 creator A5038376469 @default.
• W2265915051 creator A5045124572 @default.
• W2265915051 creator A5050228664 @default.
• W2265915051 creator A5058869199 @default.
• W2265915051 creator A5063660245 @default.
• W2265915051 creator A5086565742 @default.
• W2265915051 creator A5090326578 @default.
• W2265915051 date "2010-05-20" @default.
• W2265915051 modified "2023-09-27" @default.
• W2265915051 title "Use of chemotherapy and immunotherapy in the last two months of life in a French institutional anticancer center, 2008-2009." @default.
• W2265915051 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e19656" @default.
• W2265915051 hasPublicationYear "2010" @default.
• W2265915051 type Work @default.
• W2265915051 sameAs 2265915051 @default.
• W2265915051 citedByCount "2" @default.
• W2265915051 crossrefType "journal-article" @default.
• W2265915051 hasAuthorship W2265915051A5019873099 @default.
• W2265915051 hasAuthorship W2265915051A5022732830 @default.
• W2265915051 hasAuthorship W2265915051A5037206907 @default.
• W2265915051 hasAuthorship W2265915051A5038376469 @default.
• W2265915051 hasAuthorship W2265915051A5045124572 @default.
• W2265915051 hasAuthorship W2265915051A5050228664 @default.
• W2265915051 hasAuthorship W2265915051A5058869199 @default.
• W2265915051 hasAuthorship W2265915051A5063660245 @default.
• W2265915051 hasAuthorship W2265915051A5086565742 @default.
• W2265915051 hasAuthorship W2265915051A5090326578 @default.
• W2265915051 hasConcept C121608353 @default.
• W2265915051 hasConcept C126322002 @default.
• W2265915051 hasConcept C141071460 @default.
• W2265915051 hasConcept C2776694085 @default.
• W2265915051 hasConcept C2778336483 @default.
• W2265915051 hasConcept C2779134260 @default.
• W2265915051 hasConcept C2779399171 @default.
• W2265915051 hasConcept C2781413609 @default.
• W2265915051 hasConcept C71924100 @default.
• W2265915051 hasConceptScore W2265915051C121608353 @default.
• W2265915051 hasConceptScore W2265915051C126322002 @default.
• W2265915051 hasConceptScore W2265915051C141071460 @default.
• W2265915051 hasConceptScore W2265915051C2776694085 @default.
• W2265915051 hasConceptScore W2265915051C2778336483 @default.
• W2265915051 hasConceptScore W2265915051C2779134260 @default.
• W2265915051 hasConceptScore W2265915051C2779399171 @default.
• W2265915051 hasConceptScore W2265915051C2781413609 @default.
• W2265915051 hasConceptScore W2265915051C71924100 @default.
• W2265915051 hasIssue "15_suppl" @default.
• W2265915051 hasLocation W22659150511 @default.
• W2265915051 hasOpenAccess W2265915051 @default.
• W2265915051 hasPrimaryLocation W22659150511 @default.
• W2265915051 hasRelatedWork W2070505874 @default.
• W2265915051 hasRelatedWork W2347614275 @default.
• W2265915051 hasRelatedWork W2356680716 @default.
• W2265915051 hasRelatedWork W2360013941 @default.
• W2265915051 hasRelatedWork W2364114640 @default.
• W2265915051 hasRelatedWork W2376645157 @default.
• W2265915051 hasRelatedWork W2384740383 @default.
• W2265915051 hasRelatedWork W2889443765 @default.
• W2265915051 hasRelatedWork W3106263696 @default.
• W2265915051 hasRelatedWork W1540236315 @default.
• W2265915051 hasVolume "28" @default.
• W2265915051 isParatext "false" @default.
• W2265915051 isRetracted "false" @default.
• W2265915051 magId "2265915051" @default.
• W2265915051 workType "article" @default.